Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (371-380 of 453) with videos related to

Pageof 46
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology|October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeMorris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.
Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Neuro-Oncology|March 1, 2021
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastomaPaul D Brown, Caroline Chung, Diane D Liu, et al.
Journal of Geriatric Oncology|August 30, 2022
Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive studyDilorom Sass, Elizabeth Vera, Anna Choi, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Pageof 46

Showing results (371-380 of 453) with videos related to

Sort By:
Pageof 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology|October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeMorris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.
Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Neuro-Oncology|March 1, 2021
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastomaPaul D Brown, Caroline Chung, Diane D Liu, et al.
Journal of Geriatric Oncology|August 30, 2022
Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive studyDilorom Sass, Elizabeth Vera, Anna Choi, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Pageof 46